• News & Media
  • Contact
  • Home
  • About Us
    • Our Commitment
    • The Story Behind Our Name
    • Leadership
    • Board of Directors
  • Our Approach
    • Precision Medicines
    • Overcoming Resistance
    • Novel Biomarkers
  • Pipeline
    • Ziftomenib
    • Tipifarnib
    • KO-2806
    • Posters and Presentations
    • Scientific Manuscripts
    • Access To Investigational Drugs Outside a Clinical Study
  • Clinical Trials
    • Overview of Clinical Trials
    • Ziftomenib Clinical Trials
    • KOMET-001 – AML
    • KOMET-007 – AML
    • KOMET-008 – AML
    • Tipifarnib Clinical Trials
    • KURRENT-HN – HNSCC
    • KO-2806 Clinical Trials
    • FIT-001 – Solid Tumors
  • Patients & Caregivers
    • Acute Leukemias
    • Head & Neck Cancer
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Corporate Governance
    • Financial Information
    • Analyst Coverage
    • FAQs
    • Contact
  • Careers
    • Values
    • Life At Kura
    • Benefits
    • Open Positions
  • News & Media
  • Contact
  • Menu Menu

Kura Oncology 2022 Annual Report

April 20, 2023/in 2022, Kura Kommentary, Perspectives, Type, Year
Read more
https://kuraoncology.com/wp-content/uploads/Annual-Report-img.jpg 456 836 David Anderson /wp-content/uploads/kura-logo-registered-blue.svg David Anderson2023-04-20 08:00:412023-08-23 14:32:33Kura Oncology 2022 Annual Report

The History and Culture of Kura

March 21, 2023/in 2022, Life at Kura, Perspectives, Type, Year
Read more
https://kuraoncology.com/wp-content/uploads/Kura-Culture-img.jpg 456 836 David Anderson /wp-content/uploads/kura-logo-registered-blue.svg David Anderson2023-03-21 08:00:512023-08-23 14:38:29The History and Culture of Kura

SDUT San Diego Top Workplaces 2022

November 20, 2022/in 2022, Awards, Perspectives, Type, Year
Read more
https://kuraoncology.com/wp-content/uploads/SDUT-2022.png 456 836 David Anderson /wp-content/uploads/kura-logo-registered-blue.svg David Anderson2022-11-20 08:00:362023-08-24 12:09:13SDUT San Diego Top Workplaces 2022

Liquid Biopsies Guide the Development of Cancer Drugs

September 6, 2022/in 2022, Media Coverage, Perspectives, Type, Year
Read more
https://kuraoncology.com/wp-content/uploads/LiquidBiopsies_GettyImages-1325872227-1068x712-1.jpg 712 1068 eallison /wp-content/uploads/kura-logo-registered-blue.svg eallison2022-09-06 09:30:362023-08-24 09:47:55Liquid Biopsies Guide the Development of Cancer Drugs
  • About Us
  • Our Commitment
  • The Story Behind Our Name
  • Leadership
  • Board of Directors
  • Our Approach
  • Precision Medicines
  • Overcoming Resistance
  • Novel Biomarkers
  • Pipeline
  • Ziftomenib
  • Tipifarnib
  • KO-2806
  • Posters and Presentations
  • Scientific Manuscripts
  • Access to Investigational Drugs Outside a Clinical Study
  • Clinical Trials
  • Overview of Clinical Trials
  • Ziftomenib Clinical Trials
  • KOMET-001 – AML
  • KOMET-007 – AML
  • KOMET-008 – AML
  • Tipifarnib Clinical Trials
  • KURRENT-HN – HNSCC
  • KO-2806 Clinical Trials
  • FIT-001 – Solid Tumors
  • Patients & Caregivers
  • Acute Leukemias
  • Head & Neck Cancer
  • Investors
  • Overview
  • Press Releases
  • Events & Presentations
  • Corporate Governance
  • Financial Information
  • Analyst Coverage
  • FAQs
  • Contact
  • Careers
  • Values
  • Life at Kura
  • Benefits
  • Open Positions
  • News & Media
  • Press Releases
  • News & Perspectives
  • Expert Perspectives
  • Media Resources
  • Contact

Kura Oncology, Inc.
12730 High Bluff Drive, Suite 400
San Diego, CA 92130
(858) 500-8800

Kura Oncology, Inc.
2 Seaport Lane, Suite 8A
Boston, MA 02210
(617) 588-3755

Kura Oncology, Inc.
5510 Morehouse Drive, Suite 110
San Diego, California 92121

© 2025 Kura Oncology, Inc. All Rights Reserved | Terms of Use | Privacy Policy

Scroll to top Scroll to top Scroll to top